United Therapeutics Loses Process-Patent Ruling in Liquidia Case

United Therapeutics Corp. is unable to lean on a presumption that Liquidia Technologies Inc.'s Yutrepia is prepared using a process claimed in one of three patents at issue in an infringement case over competing treatments for high blood pressure in the lungs, a federal judge in Delaware ruled.

Judge Richard G. Andrews denied UTC’s request that he apply a legal presumption that Yutrepia, a rival to UTC’s Tyvaso, is made using the process claimed in the patent, according to an opinion Tuesday in the U.S. District Court for the District of Delaware. A three-day bench trial is set to start ...